Resveratrol Analog 4-Bromo-Resveratrol Inhibits Gastric Cancer Stemness through the SIRT3-c-Jun N-Terminal Kinase Signaling Pathway

• Published in: Current issues in molecular biology Vol. 44; no. 1; pp. 63 - 72
• Main Authors: Tai, Yun-Shen, Ma, Yi-Shih, Chen, Chun-Lin, Tsai, Hsin-Yi, Tsai, Chin-Chuan, Wu, Meng-Chieh, Chen, Chih-Yi, Lin, Ming-Wei
• Format: Journal Article
• Language: English
• Published: MDPI 22.12.2021; MDPI AG
• Subjects: 4-bromo-resveratrol; cancer stemness; chemosensitivity; gastric cancer
• ISSN: 1467-3045; 1467-3037; 1467-3045
• DOI: 10.3390/cimb44010005

Chemotherapy is the treatment of choice for gastric cancer, but the currently available therapeutic drugs have limited efficacy. Studies have suggested that gastric cancer stem cells may play a key role in drug resistance in chemotherapy. Therefore, new agents that selectively target gastric cancer stem cells in gastric tumors are urgently required. Sirtuin-3 (SIRT3) is a deacetylase that regulates mitochondrial metabolic homeostasis to maintain stemness in glioma stem cells. Targeting the mitochondrial protein SIRT3 may provide a novel therapeutic option for gastric cancer treatment. However, the mechanism by which stemness is regulated through SIRT3 inhibition in gastric cancer remains unknown. We evaluated the stemness inhibition ability of the SIRT3 inhibitor 4′-bromo-resveratrol (4-BR), an analog of resveratrol in human gastric cancer cells. Our results suggested that 4-BR inhibited gastric cancer cell stemness through the SIRT3-c-Jun N-terminal kinase pathway and may aid in gastric cancer stem-cell–targeted therapy.